[go: up one dir, main page]

MA29744B1 - Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree - Google Patents

Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree

Info

Publication number
MA29744B1
MA29744B1 MA30659A MA30659A MA29744B1 MA 29744 B1 MA29744 B1 MA 29744B1 MA 30659 A MA30659 A MA 30659A MA 30659 A MA30659 A MA 30659A MA 29744 B1 MA29744 B1 MA 29744B1
Authority
MA
Morocco
Prior art keywords
medicaments
solid dosage
dosage formulations
improved oral
oral adsorption
Prior art date
Application number
MA30659A
Other languages
English (en)
Inventor
Federico Stroppolo
Shahbaz Ardalan
Original Assignee
Alpex Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpex Pharma S A filed Critical Alpex Pharma S A
Publication of MA29744B1 publication Critical patent/MA29744B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique sous la forme d'un comprimé pouvant se dissoudre dans la cavité buccale. Cette composition comprend (i) une dose efficace d'un ingrédient actif narcotique, et (ii) une aminé pharmaceutiquement acceptable présentant une valeur pK supérieure ou égale à environ 8, le rapport molaire entre l¿amine et l'ingrédient actif étant d'au moins environ 5:1.
MA30659A 2005-07-22 2008-02-18 Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree MA29744B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/186,925 US20070020186A1 (en) 2005-07-22 2005-07-22 Solid dosage formulations of narcotic drugs having improved buccal adsorption

Publications (1)

Publication Number Publication Date
MA29744B1 true MA29744B1 (fr) 2008-09-01

Family

ID=37440618

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30659A MA29744B1 (fr) 2005-07-22 2008-02-18 Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree

Country Status (26)

Country Link
US (3) US20070020186A1 (fr)
EP (1) EP1906961B1 (fr)
JP (1) JP5714797B2 (fr)
KR (1) KR101326206B1 (fr)
CN (1) CN101208091A (fr)
AU (1) AU2006271870B2 (fr)
BR (1) BRPI0613769A2 (fr)
CA (1) CA2607360C (fr)
CY (1) CY1117470T1 (fr)
DK (1) DK1906961T3 (fr)
ES (1) ES2569228T3 (fr)
HR (1) HRP20160327T1 (fr)
HU (1) HUE027354T2 (fr)
IL (1) IL187387A (fr)
MA (1) MA29744B1 (fr)
MX (1) MX2007015480A (fr)
NO (1) NO20080827L (fr)
NZ (1) NZ563511A (fr)
PL (1) PL1906961T3 (fr)
RS (1) RS54670B1 (fr)
RU (1) RU2408373C2 (fr)
SI (1) SI1906961T1 (fr)
TW (1) TW200727922A (fr)
UA (1) UA90518C2 (fr)
WO (1) WO2007009806A2 (fr)
ZA (1) ZA200710406B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
EP2152315B1 (fr) 2007-05-25 2016-01-06 Indivior UK Limited Formulations d'administration prolongée de composés de rispéridone
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP2440210A4 (fr) 2009-06-12 2014-01-29 Meritage Pharma Inc Procédés de traitement de troubles gastro-intestinaux
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
WO2014011830A1 (fr) * 2012-07-12 2014-01-16 Mallinckrodt Llc Compositions pharmaceutiques de dissuasion d'abus à libération prolongée
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
SG11201704797TA (en) 2014-12-23 2017-07-28 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
WO2020068510A1 (fr) 2018-09-25 2020-04-02 SpecGx LLC Formes posologiques de capsules à libération immédiate anti-abus

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
CA2259418A1 (fr) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Composition pharmaceutique contenant un sel d'addition acide d'un medicament de base
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
US5958453A (en) 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
AU8977698A (en) 1997-07-25 1999-02-16 Elan Corporation, Plc A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
JP2000281589A (ja) 1999-03-26 2000-10-10 T T S Gijutsu Kenkyusho:Kk 経粘膜吸収助剤
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US20030219494A1 (en) * 2002-03-20 2003-11-27 Smith Maree Therese Compositions and methods of using them
CA2479735C (fr) * 2002-03-20 2011-05-17 Elan Pharma International Ltd. Formes posologiques a dissolution rapide presentant une friabilite reduite
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US20040202698A1 (en) 2003-04-02 2004-10-14 The Procter & Gamble Company Drug delivery systems comprising an encapsulated active ingredient
CA2524806C (fr) * 2003-05-07 2011-07-12 Akina, Inc. Granules a teneur elevee en plastique, destines a la fabrication de comprimes a dissolution rapide
WO2005065319A2 (fr) * 2003-12-31 2005-07-21 Cima Labs Inc. Forme galenique de fentanyl generalement lineaire effervescente et orale et ses procedes d'administration

Also Published As

Publication number Publication date
MX2007015480A (es) 2008-04-29
JP2009502761A (ja) 2009-01-29
SI1906961T1 (sl) 2016-09-30
AU2006271870A1 (en) 2007-01-25
US10258693B2 (en) 2019-04-16
DK1906961T3 (en) 2016-05-02
CN101208091A (zh) 2008-06-25
IL187387A (en) 2016-10-31
US20140018392A1 (en) 2014-01-16
BRPI0613769A2 (pt) 2011-02-01
WO2007009806A3 (fr) 2007-04-05
TW200727922A (en) 2007-08-01
IL187387A0 (en) 2008-02-09
HUE027354T2 (en) 2016-09-28
UA90518C2 (ru) 2010-05-11
KR20080030608A (ko) 2008-04-04
ZA200710406B (en) 2008-11-26
PL1906961T3 (pl) 2016-07-29
KR101326206B1 (ko) 2013-11-08
CY1117470T1 (el) 2017-04-26
WO2007009806A2 (fr) 2007-01-25
HRP20160327T1 (hr) 2016-05-20
JP5714797B2 (ja) 2015-05-07
CA2607360C (fr) 2014-02-18
CA2607360A1 (fr) 2007-01-25
RS54670B1 (sr) 2016-08-31
US8574552B2 (en) 2013-11-05
RU2408373C2 (ru) 2011-01-10
EP1906961A2 (fr) 2008-04-09
US20070020186A1 (en) 2007-01-25
US20070020187A1 (en) 2007-01-25
EP1906961B1 (fr) 2016-03-23
AU2006271870B2 (en) 2011-11-24
NZ563511A (en) 2011-03-31
NO20080827L (no) 2008-02-15
ES2569228T3 (es) 2016-05-09
RU2007149044A (ru) 2009-06-27

Similar Documents

Publication Publication Date Title
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
WO2003105800A3 (fr) Forme galenique, se presentant sous forme de film adherant a la muqueuse, pour l'administration de principes actifs du cannabis
ATE423556T1 (de) Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen
IL165601A0 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
WO2003015531A3 (fr) Formulation pharmaceutique contenant un colorant
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MA31706B1 (fr) Formulations galéniques de composés organiques
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
CA2508611A1 (fr) Compositions de medicaments anti-inflammatoires non-steroidaux, decongestionnants et antihistaminiques
WO2005004915A3 (fr) Compositions contenant meloxicam
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
WO2002011694A3 (fr) Compositions et formes posologiques en vue d'une application dans la cavite orale dans le cadre du traitement de mycoses
WO2005117895A8 (fr) Compositions contenant de la meloxicame
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
WO2007011958A3 (fr) Formes posologiques intra-buccales de glucagon
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
AU2003257589A1 (en) Remedy for integration dysfunction syndrome
MY141008A (en) Oral formulations of deoxypeganine and their uses
SE0203817D0 (sv) New composition